301 related articles for article (PubMed ID: 3710632)
1. Study of bioavailability and pharmacokinetics of theophylline following administration of two sustained release dosage forms as assessed by salivary data: Part II.
Ohmori N; Inotsume N; Matsukura M; Higashi A; Iwaoku R; Tobino Y; Nakano M; Matsuda I
Int J Clin Pharmacol Ther Toxicol; 1986 Apr; 24(4):196-201. PubMed ID: 3710632
[TBL] [Abstract][Full Text] [Related]
2. Effect of food on bioavailability and pharmacokinetics of theophylline following administration of two sustained release dosage forms: Part I.
Ohmori N; Inotsume N; Matsukura M; Higashi A; Iwaoku R; Tobino Y; Nakano M; Matsuda I
Int J Clin Pharmacol Ther Toxicol; 1986 Mar; 24(3):148-52. PubMed ID: 3699941
[TBL] [Abstract][Full Text] [Related]
3. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system.
González MA; Straughan AB
Clin Ther; 1994; 16(5):804-14. PubMed ID: 7859239
[TBL] [Abstract][Full Text] [Related]
4. [Bioavailability of 3 theophylline delayed-release preparations. Comparison of theophylline concentrations in the serum and saliva in the steady state].
Bochsler HP; Meyer UA
Schweiz Med Wochenschr; 1982 Nov; 112(47):1702-10. PubMed ID: 7178872
[TBL] [Abstract][Full Text] [Related]
5. Absorption of theophylline from conventional and sustained-release tablets.
Fagerström PO; Mellstrand T; Svedmyr N
Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
Schuppan D; Molz KH; Staib AH; Rietbrock N
Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis.
Valet SB; Schwartz RH; Brooks JG
Ann Allergy; 1983 Mar; 50(3):161-5. PubMed ID: 6829982
[TBL] [Abstract][Full Text] [Related]
8. Absorption of sustained-release theophylline tablets.
Fagerström PO; Heintz L
Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):359-62. PubMed ID: 6885207
[TBL] [Abstract][Full Text] [Related]
9. Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur.
Takagi K; Hasegawa T; Ogura Y; Yamaki K; Suzuki R; Satake T; Imaeda N; Mizukami Y
Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):530-5. PubMed ID: 3429057
[TBL] [Abstract][Full Text] [Related]
10. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
Steinijans VW; Zech K; Fischer R
Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
[TBL] [Abstract][Full Text] [Related]
11. Absorption of theophylline from conventional and sustained-release tablets.
Mellstrand T; Svedmyr N; Fagerström PO
Eur J Respir Dis Suppl; 1980; 109():54-60. PubMed ID: 6934088
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability of sustained-release theophylline formulations.
Bonora Regazzi M; Rondanelli R; Vidale E; Cristiani D
Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):245-51. PubMed ID: 6862729
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic properties of a new sustained-release theophylline preparation.
Dahlqvist R; Billing B
Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):69-72. PubMed ID: 6840927
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of three sustained-release theophylline preparations (350 mg Theograd, 350 mg Theolair Retard and 300 mg Theodur) in steady state in healthy volunteers and asthmatics--Part I: Theophylline plasma levels.
van der Vet AP; Drost RH; Kreukniet J; Maes RA
Int J Clin Pharmacol Ther Toxicol; 1984 Aug; 22(8):423-9. PubMed ID: 6490224
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of a short- and long-acting theophylline medication (theolair and Theolair retard) in normals and asthmatics. Part I: pharmacokinetics.
Utama I; Kreukniet J; Meering PG; Maes RA
Int J Clin Pharmacol Ther Toxicol; 1983 Jun; 21(6):287-91. PubMed ID: 6885202
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the plasma profiles of two slow-release theophylline preparations (Nuelin depot and Theo-dur) in healthy volunteers.
Talseth T; Boye NP; Bredesen JE; Kornstad S
Ann Allergy; 1981 May; 46(5):279-80. PubMed ID: 7235323
[TBL] [Abstract][Full Text] [Related]
18. [Bioavailability of theophylline in a new oral sustained-release preparation (author's transl)].
Schneider GF; Heese GU; Huber HJ; Janzen N; Jünger H; Moser C; Stanislaus F
Arzneimittelforschung; 1981; 31(9):1489-97. PubMed ID: 7197962
[TBL] [Abstract][Full Text] [Related]
19. The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets.
Jonkman JH; van der Boon WJ; Schoenmaker R; Holtkamp A; Thürkow-Luikens AJ
Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):506-10. PubMed ID: 6500770
[TBL] [Abstract][Full Text] [Related]
20. Effect of sustained-release on the pharmacokinetics of theophylline in healthy subjects.
Bialer M; Salame K; Raz I
Int J Clin Pharmacol Ther Toxicol; 1985 Dec; 23(12):662-7. PubMed ID: 4093206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]